EntryPoint Capital LLC Buys New Shares in Janux Therapeutics, Inc. (NASDAQ:JANX)

EntryPoint Capital LLC acquired a new position in shares of Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) in the 4th quarter, according to its most recent disclosure with the SEC. The fund acquired 12,225 shares of the company's stock, valued at approximately $655,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Rhumbline Advisers raised its position in shares of Janux Therapeutics by 1.6% during the 4th quarter. Rhumbline Advisers now owns 38,153 shares of the company's stock worth $2,043,000 after acquiring an additional 599 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its holdings in shares of Janux Therapeutics by 10.9% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 11,128 shares of the company's stock valued at $596,000 after buying an additional 1,095 shares in the last quarter. Virtu Financial LLC grew its position in shares of Janux Therapeutics by 17.5% in the 4th quarter. Virtu Financial LLC now owns 8,769 shares of the company's stock valued at $469,000 after buying an additional 1,306 shares during the last quarter. Avanza Fonder AB acquired a new stake in Janux Therapeutics during the 4th quarter worth $139,000. Finally, Zacks Investment Management raised its stake in Janux Therapeutics by 8.7% during the 3rd quarter. Zacks Investment Management now owns 42,133 shares of the company's stock worth $1,914,000 after acquiring an additional 3,360 shares in the last quarter. Institutional investors and hedge funds own 75.39% of the company's stock.

Insider Activity

In other Janux Therapeutics news, insider Andrew Hollman Meyer sold 13,334 shares of the firm's stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $54.88, for a total transaction of $731,769.92. Following the completion of the transaction, the insider now directly owns 82,139 shares in the company, valued at approximately $4,507,788.32. This trade represents a 13.97 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Ra Capital Management, L.P. bought 341,742 shares of the business's stock in a transaction on Wednesday, March 5th. The shares were acquired at an average price of $30.64 per share, with a total value of $10,470,974.88. Following the transaction, the director now owns 9,658,988 shares of the company's stock, valued at $295,951,392.32. The trade was a 3.67 % increase in their position. The disclosure for this purchase can be found here. Insiders sold a total of 25,002 shares of company stock worth $1,279,953 over the last 90 days. 29.40% of the stock is currently owned by corporate insiders.

Remove Ads

Janux Therapeutics Stock Performance

JANX stock traded down $0.68 during trading on Friday, reaching $29.10. 469,177 shares of the company were exchanged, compared to its average volume of 841,429. Janux Therapeutics, Inc. has a 52-week low of $28.91 and a 52-week high of $71.71. The company has a market cap of $1.72 billion, a P/E ratio of -24.87 and a beta of 3.23. The stock's 50 day moving average price is $35.60 and its 200 day moving average price is $45.99.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last released its quarterly earnings results on Thursday, February 27th. The company reported ($0.36) earnings per share for the quarter, topping analysts' consensus estimates of ($0.49) by $0.13. Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. As a group, equities research analysts forecast that Janux Therapeutics, Inc. will post -1.38 EPS for the current year.

Wall Street Analysts Forecast Growth

JANX has been the subject of several research reports. Wedbush reissued an "outperform" rating and issued a $76.00 target price (up from $75.00) on shares of Janux Therapeutics in a report on Friday, February 28th. HC Wainwright reaffirmed a "buy" rating and issued a $70.00 target price on shares of Janux Therapeutics in a report on Monday, March 3rd. BTIG Research raised their price objective on shares of Janux Therapeutics from $82.00 to $100.00 and gave the stock a "buy" rating in a research report on Tuesday, December 3rd. Stifel Nicolaus upped their target price on shares of Janux Therapeutics from $70.00 to $115.00 and gave the company a "buy" rating in a report on Tuesday, December 3rd. Finally, Leerink Partners boosted their price target on Janux Therapeutics from $79.00 to $91.00 and gave the company an "outperform" rating in a research report on Tuesday, December 3rd. One equities research analyst has rated the stock with a hold rating, nine have given a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of "Buy" and an average price target of $92.44.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.